Alto Neuroscience completes patient enrollment in ALTO-101 trial

Alto Neuroscience (ANRO) announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 inhibitor, for the treatment of cognitive impairment associated with schizophrenia. Topline data from the Phase 2 proof-of-concept study are expected following completion of dosing and data analysis and are anticipated to guide future development decisions for ALTO-101.